ORIGINAL
Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España
Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain
I. Elíasa, N. Ortega-Joaquína, P. de la Cuevab, L.J. del Pozoc, D. Moreno-Ramírezd, A. Boadae, M. Aguilarf, A. Miradag, E. Mosquerag, C. Gibbonsh, I. Oyagüeza,
Autor para correspondencia
a Pharmacoeconomics & Outcomes Research Iberia, Madrid, España
b Departamento de Dermatología, Hospital Universitario Infanta Leonor, Madrid, España
c Departamento de Dermatología, Hospital Universitario Son Espases, Mallorca, España
d Departamento de Dermatología, Hospital Universitario Virgen de la Macarena, Sevilla, España
e Departamento de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, España
f Departamento de Dermatología, Hospital Costa del Sol, Marbella, Málaga, España
g Laboratorios LEO Pharma, S. A., Barcelona, España
h LEO Pharma, Berkshire, Reino Unido
Leído
9436
Vecesse ha leído el artículo
2694
Total PDF
6742
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 186 | 14 | 200 |
| 2025 5 | 164 | 32 | 196 |
| 2025 4 | 160 | 23 | 183 |
| 2025 3 | 136 | 26 | 162 |
| 2025 2 | 181 | 31 | 212 |
| 2025 1 | 102 | 33 | 135 |
| 2024 12 | 106 | 23 | 129 |
| 2024 11 | 106 | 59 | 165 |
| 2024 10 | 72 | 47 | 119 |
| 2024 9 | 77 | 40 | 117 |
| 2024 8 | 75 | 68 | 143 |
| 2024 7 | 70 | 56 | 126 |
| 2024 6 | 97 | 30 | 127 |
| 2024 5 | 72 | 39 | 111 |
| 2024 4 | 94 | 52 | 146 |
| 2024 3 | 65 | 33 | 98 |
| 2024 2 | 58 | 32 | 90 |
| 2024 1 | 93 | 32 | 125 |
| 2023 12 | 70 | 19 | 89 |
| 2023 11 | 67 | 37 | 104 |
| 2023 10 | 45 | 32 | 77 |
| 2023 9 | 42 | 52 | 94 |
| 2023 8 | 40 | 14 | 54 |
| 2023 7 | 53 | 35 | 88 |
| 2023 6 | 55 | 23 | 78 |
| 2023 5 | 72 | 28 | 100 |
| 2023 4 | 36 | 22 | 58 |
| 2023 3 | 82 | 36 | 118 |
| 2023 2 | 74 | 37 | 111 |
| 2022 1 | 52 | 43 | 95 |
| 2022 12 | 98 | 36 | 134 |
| 2022 11 | 95 | 49 | 144 |
| 2022 10 | 105 | 48 | 153 |
| 2022 9 | 78 | 70 | 148 |
| 2022 8 | 66 | 53 | 119 |
| 2022 7 | 108 | 87 | 195 |
| 2022 6 | 140 | 54 | 194 |
| 2022 5 | 164 | 75 | 239 |
| 2022 4 | 246 | 47 | 293 |
| 2022 3 | 202 | 65 | 267 |
| 2022 2 | 215 | 41 | 256 |
| 2021 1 | 207 | 62 | 269 |
| 2021 12 | 146 | 72 | 218 |
| 2021 11 | 152 | 55 | 207 |
| 2021 10 | 135 | 67 | 202 |
| 2021 9 | 126 | 56 | 182 |
| 2021 8 | 94 | 34 | 128 |
| 2021 7 | 97 | 34 | 131 |
| 2021 6 | 110 | 52 | 162 |
| 2021 5 | 113 | 51 | 164 |
| 2021 4 | 201 | 100 | 301 |
| 2021 3 | 113 | 39 | 152 |
| 2021 2 | 115 | 26 | 141 |
| 2020 1 | 93 | 31 | 124 |
| 2020 12 | 88 | 27 | 115 |
| 2020 11 | 74 | 32 | 106 |
| 2020 10 | 76 | 20 | 96 |
| 2020 9 | 82 | 33 | 115 |
| 2020 8 | 58 | 30 | 88 |
| 2020 7 | 64 | 16 | 80 |
| 2020 6 | 68 | 35 | 103 |
| 2020 5 | 89 | 25 | 114 |
| 2020 4 | 55 | 24 | 79 |
| 2020 3 | 53 | 30 | 83 |
| 2020 2 | 4 | 0 | 4 |
| 2019 12 | 1 | 2 | 3 |
| 2019 5 | 3 | 2 | 5 |
| 2019 4 | 4 | 4 | 8 |
| 2019 3 | 4 | 5 | 9 |
| 2019 2 | 1 | 0 | 1 |
| 2018 11 | 6 | 5 | 11 |
| 2018 10 | 2 | 1 | 3 |
| 2018 9 | 4 | 0 | 4 |
| 2018 8 | 0 | 1 | 1 |
| 2018 7 | 1 | 0 | 1 |
| 2018 2 | 13 | 1 | 14 |
| 2018 1 | 10 | 0 | 10 |
| 2017 12 | 15 | 0 | 15 |
| 2017 11 | 16 | 0 | 16 |
| 2017 10 | 11 | 0 | 11 |
| 2017 9 | 17 | 1 | 18 |
| 2017 8 | 7 | 0 | 7 |
| 2017 7 | 3 | 2 | 5 |
| 2017 6 | 13 | 0 | 13 |
| 2017 5 | 6 | 0 | 6 |
| 2017 4 | 12 | 2 | 14 |
| 2017 3 | 5 | 2 | 7 |
| 2017 2 | 3 | 1 | 4 |
| 2016 1 | 7 | 0 | 7 |
| 2016 12 | 10 | 2 | 12 |
| 2016 11 | 11 | 1 | 12 |
| 2016 10 | 7 | 4 | 11 |
| 2016 9 | 5 | 7 | 12 |
| 2016 8 | 6 | 4 | 10 |
| 2016 7 | 7 | 23 | 30 |
Mostrar todo
